Paper Details

  1. Home
  2. Paper Details

Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.

Author: BelknapRobert, BorisovAndrey, CaylàJoan A, ChenMichael P, GandhiNeel R, HollandDavid P, MilletJoan Pau, MoroRuth N, SadowskiClaire, ScottNigel A, WrightAlicia

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rifapentine plus isoniazid (3HP) is a recommended treatment for latent tuberculosis infection (LTBI), but its effects on symptoms and side effects are not fully understood. This study aimed to determine patterns of symptom development and identify systemic drug reactions (SDRs) in patients taking 3HP. While more research is needed, this study provides valuable information about the potential side effects and symptom development associated with 3HP treatment.
Paper Details　
Original Abstract of the Article :
Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide. The development of symptoms and systemic drug reactions (SDRs) on 3HP have not been fully characterized. We aimed to determine the patterns of symptom development and id...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273365/

データ提供：米国国立医学図書館（NLM）

Latent Tuberculosis Infection: A Journey Through the Desert of Silent Infection

Latent tuberculosis infection (LTBI) can feel like navigating a vast and unforgiving desert of silent infection, where the threat of active disease lurks unseen. This research examines the development of symptoms and systemic drug reactions (SDRs) in individuals receiving weekly rifapentine plus isoniazid (3HP) treatment for LTBI. The study aimed to characterize the patterns of symptom development and identify SDRs associated with 3HP therapy.

Navigating the Desert of LTBI Treatment

The study revealed that 3HP treatment for LTBI can be associated with a range of symptoms and SDRs, highlighting the need for careful monitoring and management. The research team's findings underscore the importance of educating patients about potential side effects and promptly addressing any concerns or adverse reactions. This research provides valuable insights into the potential risks and benefits of 3HP treatment for LTBI.

The Importance of Vigilance in the Desert of Silent Infection

This research emphasizes the importance of vigilance in managing LTBI. It reminds us that even with effective treatment, there is a risk of developing symptoms or experiencing adverse reactions. By working closely with healthcare professionals and promptly reporting any concerns, individuals can minimize the potential risks associated with LTBI treatment and navigate the desert of silent infection more effectively.

Dr.Camel's Conclusion

Navigating the desert of latent tuberculosis infection can be a challenging experience, but with careful monitoring and management, individuals can improve their chances of a safe and successful treatment journey. This research highlights the importance of recognizing potential side effects and promptly addressing any concerns associated with 3HP therapy. By working closely with healthcare professionals, individuals can find a more manageable path through the desert of silent infection and achieve better overall health outcomes.

Date :
  1. Date Completed 2023-06-19
  2. Date Revised 2023-11-24
Further Info :

Pubmed ID

36815322

DOI: Digital Object Identifier

PMC10273365

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.